ReviewCurrent opinion in microbiology2016
Antisense antimicrobial therapeutics.
Review in Current opinion in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 122 citations in OpenAlex.
- Oligonucleotide genetics forbioRxiv : the preprint server for biology · 2026Article
- Developing antisense oligomer biotics "asobiotics" as precision antibacterials: designs, strategies, and considerations for future success.FEMS microbiology reviews · 2026Review
- Medical ozone: mechanisms, biological effects and clinical evidence-a narrative review.Frontiers in medicine · 2026Review
- Bridge Nucleic Acid/DNA Gapmers as Potential Inhibitors of Bacterial Gene Expression by Multiple Antisense Mechanisms: An In Vitro Study.Molecules (Basel, Switzerland) · 2025Article
- Bridge nucleic acid/DNA gapmers as inhibitors of gene expression by multiple antisense mechanisms.Research square · 2025Article
- High-Throughput Tiling of Essential mRNAs Increases Potency of Antisense Antibiotics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exploring the Therapeutic Potential: Antisense RNA Delivery Via Bacteriophage Platform.Iranian journal of biotechnology · 2025Review
- Targeted inhibition of E. coli adhesion using antisense oligonucleotides: an approach to combat bacteria via CsrB targeting.World journal of microbiology & biotechnology · 2025Article
- Parallel and Automated PNA Synthesis in μSPOT Format.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Chemical strategies for antisense antibiotics.Chemical Society reviews · 2024Review
- Identifying Cell-Penetrating Peptides for Effectively Delivering Antimicrobial Molecules intoAntibiotics (Basel, Switzerland) · 2024Article
- Promising strategies employing nucleic acids as antimicrobial drugs.Molecular therapy. Nucleic acids · 2024Review
- General and Specific Cytotoxicity of Chimeric Antisense Oligonucleotides in Bacterial Cells and Human Cell Lines.Antibiotics (Basel, Switzerland) · 2024Article
- RNA-based medicine: from molecular mechanisms to therapy.The EMBO journal · 2023Review
- Strategies to combat Gram-negative bacterial resistance to conventional antibacterial drugs: a review.Osong public health and research perspectives · 2023Article
- Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation.RSC medicinal chemistry · 2023Review
- A network of small RNAs regulates sporulation initiation in Clostridioides difficile.The EMBO journal · 2023Article
- Combined Application of Antisense Oligomers to Control Transcription Factors of Candida albicans Biofilm Formation.Mycopathologia · 2023Article
- Design and off-target prediction for antisense oligomers targeting bacterial mRNAs with the MASON web server.RNA (New York, N.Y.) · 2023Article
- Chemistry, structure and function of approved oligonucleotide therapeutics.Nucleic acids research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antisense antimicrobial therapeutics are synthetic oligomers that silence expression of specific genes. This specificity confers an advantage over broad-spectrum antibiotics by avoiding unintended effects on commensal bacteria. The sequence-specificity and short length of antisense antimicrobials also pose little risk to human gene expression. Because antisense antimicrobials are a platform technology, they can be rapidly designed and synthesized to target almost any microbe. This reduces drug discovery time, and provides flexibility and a rational approach to drug development. Recent work has shown that antisense technology has the potential to address the antibiotic-resistance crisis, since resistance mechanisms for standard antibiotics apparently have no effect on antisense antimicrobials. Here, we describe current reports of antisense antimicrobials targeted against viruses, parasites, and bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.